Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc.
Your view on KYMR
Overview
What the company does, where it operates, and who runs it.
About Kymera Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Nello Mainolfi
- Headquarters
- 200 Arsenal Yards Boulevard, Watertown, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Nello Mainolfi
- Headquarters
- 200 Arsenal Yards Boulevard, Watertown, MA, US
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Kymera Therapeutics, Inc., and the rating behind it. KYMR last traded at $114.96; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Kymera Therapeutics, Inc.. Starting points for Kymera Therapeutics, Inc.: EPS -$3.05, beta 1.97 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Kymera Therapeutics, Inc.. Kymera Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Kymera Therapeutics, Inc.. Trailing twelve-month EPS for Kymera Therapeutics, Inc. stands at -$3.05. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Kymera Therapeutics, Inc.. Kymera Therapeutics, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Kymera Therapeutics, Inc. valued side by side against its closest peers. Kymera Therapeutics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Kymera Therapeutics, Inc., and how their positions are changing. At a $9.46B market value, institutional positions materially move Kymera Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Kymera Therapeutics, Inc. executives and directors. Shares of Kymera Therapeutics, Inc. have traded between $19.45 and $68.45 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Kymera Therapeutics, Inc.. Kymera Therapeutics, Inc. is a $9.46B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Kymera Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Kymera Therapeutics, Inc.. Coverage tracks Kymera Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.